Viridian Therapeutics, Inc. Common Stock
Here’s whether Viridian Therapeutics, Inc. Common Stock (VRDN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 63 — healthy momentum range; strong 1-year return of +26.1%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.71% over 10 days); 3-month momentum negative (-41.4%). Currently 49.7% off its 52-week high. Score: -3/7.
VRDN is trading below its 200-day MA ($24.31) — a key warning sign the longer-term trend is under pressure. An RSI of 63.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +26.1% compares to +27.9% for SPY (trailed the market by 1.8%). The current 49.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.